Raymond Parrish, MD
Pulmonary Disease · Aurora, CONPI 1093202517
Payments from drug & device makers
What this record shows
This record is dominated by grants: $12,500 of the $14,125 with a category attached, or 88.5%. Boston Scientific accounts for 89.2% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $12,750 and has fallen 90.3% since, to $1,236 in 2025.
Across 16 payments — averaging $882.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$13K
- Pulmonx Corporation$619
- Intuitive Surgical$306
- Olympus America Inc.$195
- ERBE USA Inc$111
- Pinnacle Biologics, Inc$106
- plus $187 from 2 others
What the payments were for
- Grants$12,50088%
- Travel & lodging$941%
- Food & beverage$1,53111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 3 | $12,600 |
| Pulmonx Corporation | 4 | $619 |
| Intuitive Surgical | 3 | $306 |
| Olympus America Inc. | 2 | $195 |
| ERBE USA Inc | 1 | $111 |
| Pinnacle Biologics, Inc | 1 | $106 |
| Cook Incorporated | 1 | $94 |
| Cook Medical LLC | 1 | $93 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CHARTIS CATHETER$611
- ZEPHYR DELIVERY CATHETER$611
- ZEPHYR ENDOBRONCHIAL VALVE$611
- PULMONX CHARTIS TABLET CONSOLE$611
- Da Vinci Surgical System$239
- Single-Use flexible Video Bronchoscope$150
- VIO3/APC3/ERBECRYO2$111
- Photofrin$106
How this compares
$14,125 in reported general payments places this provider in the 80th percentile of 248 pulmonary disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $17,878 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 23 | $4,596 |
| Montelukast Sodium | 14 | $270 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $179 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Aurora
- David SchwartzAurora$471K
- David BadeschAurora$134K
- Robert WinnAurora$70K
- Richard AlbertAurora$64K
- Joyce LeeAurora$63K
- Kevin DavidsonAurora$19K
- Melanie KoenigshoffAurora$15K
- Nina ThomasAurora$14K
- Brian GrahamAurora$14K
- Michael WechslerDenver$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.